

## CORRIGENDA

### Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia

E Jabbour, M Deininger and A Hochhaus

*Leukemia* (2011) **25**, 385; doi:10.1038/leu.2010.252

**Correction to:** *Leukemia* advance online publication, 23 September 2010; doi:10.1038/leu.2010.215

Since the publication of this paper, the authors have noticed an error on page 3 of their article. The correct sentence is shown below:

'In the phase III study of nilotinib versus imatinib as first-line treatment for patients with CP CML, patients receiving imatinib

were more likely to experience all-grade peripheral edema, eyelid edema and periorbital edema (14, 13 and 12%, respectively) than patients receiving nilotinib 300 mg twice daily (5, 1 and <1%, respectively) or nilotinib 400 mg twice daily (5, 2 and 1%, respectively).'

The authors apologize for any inconvenience caused.

### Automated pattern-guided principal component analysis vs expert-based immunophenotypic classification of B-cell chronic lymphoproliferative disorders: a step forward in the standardization of clinical immunophenotyping

ES Costa, CE Pedreira, S Barrena, Q Lecrevisse, J Flores, S Quijano, J Almeida, M del Carmen García-Macias, S Bottcher, JJM Van Dongen and A Orfao on behalf of the EuroFlow Consortium

*Leukemia* (2011) **25**, 385; doi:10.1038/leu.2010.296

**Correction to:** *Leukemia* (2010) **11**, 1927–1933; doi:10.1038/leu.2010.160

Since the publication of the above paper, the authors have noticed an error in Supplementary Tables 1 and 3.

The authors would like to apologise for any inconvenience this may have caused.

The corrected supplementary tables can be accessed via the online version of this corrigendum.